All sponsors

Seagen, a wholly owned subsidiary of Pfizer $PFE

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS12
PHASE 3 / 2-36
RECRUITING1
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO67%

Delay Index: of 12 active trials registered more than a year ago, 8 have moved their primary completion (readout) date by more than 6 months since first registration (median +10.2 months). See all sponsors →

Open Seagen, a wholly owned subsidiary of Pfizer on the live radar map → 📅 $PFE readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
tucatinib
NCT03975647
P3Active, not recruitingHER2-positive Breast Cancer4662023-06-29 (-9 mo)
tucatinib
NCT04579380
P2Active, not recruitingUterine Neoplasms; Uterine Cervical Neoplasms2172023-11-01 (+9 mo)
tucatinib
NCT04430738
P2Active, not recruitingColorectal Carcinoma; Gastric Adenocarcinoma402024-07-31 (+38 mo)
HER2CLIMB-05
NCT05132582
P3Active, not recruitingHER2 Positive Breast Cancer6542025-09-05 (+10 mo)
ECHELON-3
NCT04404283
P3Active, not recruitingDiffuse Large B-cell Lymphoma2402026-01-23 (+38 mo)
innovaTV 207
NCT03485209
P2Active, not recruitingColorectal Neoplasms; Carcinoma, Non-Small-Cell Lung3502026-03-20 (+72 mo)
disitamab vedotin
NCT06003231
P2Active, not recruitingCarcinoma, Non-Small-Cell Lung; Ovarian Neoplasms1202026-03-27 (-2 mo)
sigvotatug vedotin
NCT06012435
P3Active, not recruitingCarcinoma, Non-Small-Cell Lung7622026-05-18 (-6 mo)
disitamab vedotin
NCT04879329
P2RecruitingUrothelial Carcinoma3722026-12-11 (+46 mo)
disitamab vedotin
NCT05911295
P3Active, not recruitingUrothelial Carcinoma4122027-01-29 (+7 mo)
MOUNTAINEER-03
NCT05253651
P3Active, not recruitingColorectal Neoplasms4002027-12-31 (+28 mo)
disitamab vedotin
NCT06157892
P2Active, not recruitingBreast Neoplasms; Gastroesophageal Junction Adenocarcinoma542029-07-28 (-6 mo)